A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

This Phase III, randomized, double-blind study compares the efficacy and safety of SCTB14 versus pembrolizumab as first-line treatment in patients with driver gene-negative, TPS ≥10% locally advanced or metastatic non-small cell lung cancer (NSCLC). The primary objective is to assess superiority of SCTB14 over pembrolizumab in prolonging progression-free survival. Safety will be closely monitored.

NCT Number	NCT07362459
Lead Sponsor	Sinocelltech Ltd.
Conditions	Non-Small Cell Lung Carcinoma (NSCLC)
Enrollment	246 participants
Start Date	2025-12-30
Primary Completion	2027-07 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-01-23